Michael Mano Biography and Net Worth

Executive Vice President, Chief Legal Officer and Secretary of Karyopharm Therapeutics

Mike joined Karyopharm in December 2020 as Senior Vice President, General Counsel. In his role, Mike leads the legal and compliance functions at Karyopharm, including corporate governance, intellectual property, SEC reporting, global compliance, privacy, and general legal support of all other business activities. Prior to joining Karyopharm, Mike served as Counsel, Business Development for Biogen Inc., where he supported Biogen’s global business development platform. Mike started his legal career at Kirkland & Ellis LLP in Chicago. Mike received a Bachelor of Arts in Political Science and Sociology from Saint Michael’s College and a Juris Doctor from Washington University School of Law.

What is Michael Mano's net worth?: The estimated net worth of Michael Mano is at least $204.18 thousand as of September 15th, 2025. Mr. Mano owns 21,425 shares of Karyopharm Therapeutics stock worth more than $204,180 as of July 16th. This net worth approximation does not reflect any other assets that Mr. Mano may own. Learn More about Michael Mano's net worth.
How do I contact Michael Mano?: The corporate mailing address for Mr. Mano and other Karyopharm Therapeutics executives is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. Karyopharm Therapeutics can also be reached via phone at (617) 658-0600 and via email at [email protected]. Learn More on Michael Mano's contact information.
Has Michael Mano been buying or selling shares of Karyopharm Therapeutics?: Michael Mano has not been actively trading shares of Karyopharm Therapeutics within the last three months. Most recently, Michael Mano sold 234 shares of the business's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $6.43, for a transaction totalling $1,504.62. Following the completion of the sale, the senior vice president now directly owns 21,425 shares of the company's stock, valued at $137,762.75. Learn More on Michael Mano's trading history.
Who are Karyopharm Therapeutics' active insiders?: Karyopharm Therapeutics' insider roster includes Garen Bohlin (Director), Michael Kauffman (Director), Michael Mano (Executive Vice President, Chief Legal Officer and Secretary), Michael Mason (CFO), Stephen Mitchener (SVP), Sharon Shacham (Insider), and Jatin Shah (EVP). Learn More on Karyopharm Therapeutics' active insiders.
Are insiders buying or selling shares of Karyopharm Therapeutics?: During the last twelve months, insiders at the sold shares 12 times. They sold a total of 2,958 shares worth more than $19,037.72. The most recent insider tranaction occured on April, 21st when EVP Reshma Rangwala sold 449 shares worth more than $4,014.06. Insiders at Karyopharm Therapeutics own 1.7% of the company. Learn More about insider trades at Karyopharm Therapeutics.
Information on this page was last updated on 4/21/2026.

Michael Mano Insider Trading History at Karyopharm Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/15/2025	Sell	234	$6.43	$1,504.62	21,425
2/29/2024	Sell	1,131	$17.55	$19,849.05	18,761
9/1/2023	Sell	259	$19.95	$5,167.05	9,482

Michael Mano Buying and Selling Activity at Karyopharm Therapeutics

Karyopharm Therapeutics Company Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $9.53

$9.38

$9.86

50 Day Range

MA: $9.15

$7.14

$10.67

2 Week Range

Now: $9.53

$3.65

$10.99

Volume

315,583 shs

Average Volume

518,590 shs

Market Capitalization

$215.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8